Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM2YGNW)

Drug Name
Dactinomycin Drug Info
Synonyms
Cosmegen; Dactinomicina; Dactinomycine; Dactinomycinum; Meractinomycin; ACT D; ACTINOMYCIN D AMP; Actactinomycin A IV; Actinomycin A IV; Actinomycin Aiv; Actinomycin I; Actinomycin IV; Actinomycin cl; Actinomycin x i; Antibiotic from Streptomyces parvullus; Chounghwamycin B; D Actinomycin; Dactinomycin D; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; Lyovac cosmegen; Oncostatin K; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin C1; Actinomycin I1; Actinomycin X 1; Actinomycin X1; HBF 386; HBF 386 meractinomycin; X 97; AD (VAN); Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin D (JP15); Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin-IV; Actinomycindioic D acid, dilactone; Acto-D; COSMEGEN (TN); Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin [USAN:BAN]; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; NP-005932; Actinomycin D deriv. of 3H-phenoxaocardazine; GNF-PF-1977; Actinomycin-[threo-val-pro-sar-meval]; Actinomyein-theo-val-pro-sar-meval; Actinomycin-(threo-val-pro-sar-meval); O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
457193
ChEBI ID
CHEMBL1554
CAS Number
CAS 50-76-0
TTD Drug ID
D0P8IV
VARIDT Drug ID
DR01203
ACDINA Drug ID
D00983

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Lysosome 2.35 0.00e+0 115/128 (89.84%) CTSZ;PPT1;LAMP3;...
Arginine and proline metabolism 2.29 0.00e+0 39/50 (78%) MAOA;ALDH3A2;CKB;...
ECM-receptor interaction 2.25 0.00e+0 80/88 (90.91%) COL1A2;ITGA4;THBS2;...
Valine, leucine and isoleucine degradation 2.20 0.00e+0 42/48 (87.5%) ALDH3A2;ALDH7A1;OXCT1;...
Oxidative phosphorylation 2.20 0.00e+0 93/133 (69.92%) NDUFA7;ATP6AP1;ATP6V0B;...
Histidine metabolism 2.07 0.00e+0 16/22 (72.73%) MAOA;ALDH3A2;AOC1;...
Complement and coagulation cascades 2.07 0.00e+0 76/85 (89.41%) CFB;SERPING1;SERPINA1;...
Glutathione metabolism 2.02 0.00e+0 43/57 (75.44%) GPX1;PGD;GSTP1;...
Glycine, serine and threonine metabolism 2.02 0.00e+0 31/40 (77.5%) MAOA;PSAT1;AMT;...
Phagosome 2.02 0.00e+0 118/152 (77.63%) HLA-DQA1;THBS2;ITGB5;...
Biosynthesis of unsaturated fatty acids 1.99 1.12e-3 21/27 (77.78%) HACD2;SCD;HSD17B4;...
beta-Alanine metabolism 1.95 1.03e-3 25/30 (83.33%) ALDH3A2;CNDP2;ALDH7A1;...
Fatty acid degradation 1.93 9.49e-4 40/43 (93.02%) ALDH3A2;ALDH7A1;ACADM;...
Pyruvate metabolism 1.93 8.81e-4 41/47 (87.23%) ALDH3A2;GLO1;ME2;...
Other glycan degradation 1.91 8.23e-4 13/18 (72.22%) MAN2B2;HEXA;MAN2B1;...
Tryptophan metabolism 1.91 7.71e-4 35/42 (83.33%) MAOA;ALDH3A2;AOC1;...
Alanine, aspartate and glutamate metabolism 1.90 7.26e-4 27/37 (72.97%) ALDH5A1;ASNS;GLUD2;...
Fatty acid elongation 1.87 1.37e-3 19/27 (70.37%) HACD2;PPT1;ACOT7;...
Pentose phosphate pathway 1.83 2.60e-3 25/30 (83.33%) PGD;H6PD;TKTL1;...
Peroxisome 1.82 3.08e-3 72/82 (87.8%) HSD17B4;PECR;MPV17;...
Retrograde endocannabinoid signaling 1.80 5.29e-3 118/148 (79.73%) GNG10;NDUFA7;GNAI2;...
Proximal tubule bicarbonate reclamation 1.75 1.07e-2 21/23 (91.3%) ATP1B3;SLC4A4;GLUD2;...
Riboflavin metabolism 1.74 1.13e-2 7/8 (87.5%) ACP5;BLVRB;ACP1
Glycolysis / Gluconeogenesis 1.73 1.39e-2 56/67 (83.58%) ALDH3A2;PCK1;ALDH7A1;...
Dilated cardiomyopathy 1.72 1.43e-2 86/96 (89.58%) ITGA4;ITGB5;TPM2;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis 1.72 1.42e-2 20/26 (76.92%) PIGT;PIGK;PIGF;...
Tyrosine metabolism 1.71 1.60e-2 30/36 (83.33%) MAOA;ALDH3B1;AOC3;...
Propanoate metabolism 1.71 1.54e-2 30/34 (88.24%) SUCLG2;HIBCH;ALDH6A1;...
One carbon pool by folate 1.69 1.83e-2 15/20 (75%) AMT;DHFR;MTR;...
Phenylalanine metabolism 1.68 1.89e-2 14/17 (82.35%) MAOA;ALDH3B1;AOC3;...
FoxO signaling pathway -1.61 3.74e-2 118/131 (90.08%) BCL6;RAF1;PLK4;...
Legionellosis -1.63 3.49e-2 51/57 (89.47%) CASP8;NFKB1;RELA;...
Spinocerebellar ataxia -1.65 3.10e-2 128/143 (89.51%) PSMD6;PSMD11;ATP2A1;...
Longevity regulating pathway -1.65 3.05e-2 90/151 (59.6%) PPARG;TSC1;HSPA1L;...
Hepatitis B -1.67 2.78e-2 151/162 (93.21%) IKBKG;PRKCA;CASP8;...
Small cell lung cancer -1.68 2.51e-2 90/92 (97.83%) PTGS2;BCL2L1;FHIT;...
Cellular senescence -1.68 2.67e-2 139/156 (89.1%) SMAD2;PPP3CC;CDK1;...
Neurotrophin signaling pathway -1.68 2.85e-2 107/119 (89.92%) NFKB1;CAMK2G;PRKCD;...
Chronic myeloid leukemia -1.71 2.42e-2 72/76 (94.74%) IKBKG;GADD45G;NFKB1;...
Viral carcinogenesis -1.72 2.42e-2 149/203 (73.4%) CDK1;IKBKG;RBL1;...
mRNA surveillance pathway -1.75 1.88e-2 71/98 (72.45%) PAPOLG;PPP2R2D;SMG7;...
Basal transcription factors -1.76 1.98e-2 37/45 (82.22%) TBPL1;TAF9;TAF4;...
Measles -1.80 1.29e-2 133/139 (95.68%) IKBKG;CASP8;NFKB1;...
Estrogen signaling pathway -1.83 1.07e-2 119/137 (86.86%) NCOA2;PRKCD;TFF1;...
TNF signaling pathway -1.84 1.21e-2 103/112 (91.96%) CSF2;MMP14;LIF;...
Transcriptional misregulation in cancer -1.85 1.15e-2 158/192 (82.29%) SS18;CXCL8;MEN1;...
IL-17 signaling pathway -1.87 1.07e-2 84/94 (89.36%) CSF2;DEFB4A;IKBKG;...
Cell cycle -1.87 1.29e-2 110/124 (88.71%) FZR1;CUL1;ESPL1;...
RNA transport -1.95 2.01e-3 128/186 (68.82%) RAN;NUP43;EIF3G;...
MicroRNAs in cancer -2.04 0.00e+0 146/310 (47.1%) TP63;APC;SLC7A1;...
Spliceosome -2.07 0.00e+0 101/150 (67.33%) SART1;SNRPD2;SF3A1;...
Ribosome biogenesis in eukaryotes -2.34 0.00e+0 52/108 (48.15%) CSNK2A1;TBL3;REXO5;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H